Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.

Currently, the creation of class- and isoform-selective modulators of biologically important targets is a particularly challenging problem because different isoforms within a protein family often show striking similarity in spatial quaternary structure, especially at the catalytic sites or binding pockets. Therefore, an understanding of both the precise three-dimensional structure of the target protein and the mechanisms of action of modulators is important for developing more effective and selective agents. In this Perspective, we discuss currently available rational design strategies for obtaining class- and isoform-selective inhibitors and we illustrate these strategies with the aid of specific examples from the recent literature. The strategies covered include: (1) target-derived (-dependent) de novo drug discovery methodologies, and (2) follow-on derivatization approaches from initially identified active molecules (hit-to-lead and lead-to-candidate efforts). We also comment on prospects for further development and integration of strategies to achieve target-specific or isoform-selective inhibition.

[1]  S. Laufer,et al.  Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. , 2015, ACS combinatorial science.

[2]  S. Knapp,et al.  Selective Bisubstrate Inhibitors with Sub‐nanomolar Affinity for Protein Kinase Pim‐1 , 2013, ChemMedChem.

[3]  A. Becker,et al.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. , 2013, Journal of medicinal chemistry.

[4]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[5]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[6]  Juswinder Singh,et al.  Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. , 2013, Journal of medicinal chemistry.

[7]  Takayoshi Suzuki,et al.  An unexpected example of protein-templated click chemistry. , 2010, Angewandte Chemie.

[8]  Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications , 2010, ChemMedChem.

[9]  S. Shuto,et al.  Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor. , 2014, ACS medicinal chemistry letters.

[10]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[11]  R. Bhat,et al.  Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. , 2014, Journal of medicinal chemistry.

[12]  Takayoshi Suzuki,et al.  An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments , 2013, Medicinal research reviews.

[13]  Hiroki Tsumoto,et al.  Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. , 2012, Journal of medicinal chemistry.

[14]  Johannes C. Hermann,et al.  Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[15]  Peng Zhan,et al.  Recent advances in the structure-based rational design of TNKSIs. , 2014, Molecular bioSystems.

[16]  Michelle S. Miller,et al.  L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ , 2013, ACS medicinal chemistry letters.

[17]  Johannes C. Hermann,et al.  Rational design of highly selective spleen tyrosine kinase inhibitors. , 2012, Journal of medicinal chemistry.

[18]  R. Liskamp,et al.  Cell-penetrating bisubstrate-based protein kinase C inhibitors. , 2013, ACS chemical biology.

[19]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[20]  Vinicius M Alves,et al.  Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. , 2014, Current topics in medicinal chemistry.

[21]  T. Steinmetzer,et al.  A new strategy for the development of highly potent and selective plasmin inhibitors. , 2012, Journal of medicinal chemistry.

[22]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[23]  Heejun Kim,et al.  Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces. , 2014, Journal of the American Chemical Society.

[24]  Michael J. Munson,et al.  Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase , 2014, The Biochemical journal.

[25]  C. Nicchitta,et al.  Development of a Grp94 inhibitor. , 2012, Journal of the American Chemical Society.

[26]  S. Haggarty,et al.  Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers , 2014, Chemical science.

[27]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[28]  Charles R. Holst,et al.  Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors. , 2012, Journal of medicinal chemistry.

[29]  J. Lisztwan,et al.  Structural definitions of Jumonji family demethylase selectivity. , 2015, Drug discovery today.

[30]  B. Katzenellenbogen,et al.  Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model , 2015, Journal of medicinal chemistry.

[31]  Jean-Pierre Marquette,et al.  A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. , 2014, Nature chemical biology.

[32]  Asad U Khan,et al.  Structure based virtual screening to discover putative drug candidates: necessary considerations and successful case studies. , 2015, Methods.

[33]  I. Ghosh,et al.  New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. , 2012, Current pharmaceutical design.

[34]  Takashi Okamoto,et al.  Identification of Highly Selective and Potent Histone Deacetylase 3 Inhibitors Using Click Chemistry-Based Combinatorial Fragment Assembly , 2013, PloS one.

[35]  Sungwoo Hong,et al.  Selective and potent small-molecule inhibitors of PI3Ks. , 2014, Future medicinal chemistry.

[36]  Adam R. Johnson,et al.  Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. , 2013, Journal of medicinal chemistry.

[37]  B. Tidor,et al.  Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.

[38]  H. Oki,et al.  Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. , 2014, Journal of medicinal chemistry.

[39]  Yukihiro Itoh,et al.  Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. , 2012, Journal of medicinal chemistry.

[40]  T. Poulos,et al.  Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. , 2009, Journal of medicinal chemistry.

[41]  M. Ghadiri,et al.  Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. , 2009, Journal of medicinal chemistry.

[42]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.

[43]  Peng Zhan,et al.  Identification of novel SIRT2-selective inhibitors using a click chemistry approach. , 2014, Bioorganic & medicinal chemistry letters.

[44]  S. Schreiber,et al.  A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. , 2011, Journal of the American Chemical Society.

[45]  Yukihiro Itoh,et al.  Small-molecular modulators of cancer-associated epigenetic mechanisms. , 2013, Molecular bioSystems.

[46]  P. Cole,et al.  A mechanism-based inactivator for histone demethylase LSD1. , 2006, Journal of the American Chemical Society.

[47]  Peng Zhan,et al.  Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. , 2013, Current medicinal chemistry.

[48]  Benjamin Fabre,et al.  Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. , 2014, Journal of medicinal chemistry.

[49]  C. Schofield,et al.  Targeting histone lysine demethylases — Progress, challenges, and the future , 2014, Biochimica et biophysica acta.

[50]  M. Slijper,et al.  Development of Selective Bisubstrate‐Based Inhibitors Against Protein Kinase C (PKC) Isozymes By Using Dynamic Peptide Microarrays , 2009, Chembiochem : a European journal of chemical biology.

[51]  Andrew J. P. White,et al.  Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. , 2012, Journal of medicinal chemistry.

[52]  Peng Zhan,et al.  Conformational restriction: an effective tactic in 'follow-on'-based drug discovery. , 2014, Future medicinal chemistry.

[53]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[54]  Qiang Huang,et al.  X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. , 2013, Journal of the American Chemical Society.

[55]  E. García-Junceda,et al.  Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance. , 2006, Journal of the American Chemical Society.

[56]  P. Cole,et al.  Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. , 2007, Biochemistry.

[57]  Yu-chian Chen Beware of docking! , 2015, Trends in pharmacological sciences.

[58]  Zhe Li,et al.  Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. , 2012, Journal of medicinal chemistry.

[59]  H. Oki,et al.  Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site. , 2014, Bioorganic & medicinal chemistry.

[60]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.

[61]  Yukihiro Itoh,et al.  Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.

[62]  T. Poulos,et al.  Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. , 2008, Journal of the American Chemical Society.

[63]  K. Kirshenbaum,et al.  Tricks with clicks: modification of peptidomimetic oligomers via copper-catalyzed azide-alkyne [3 + 2] cycloaddition. , 2010, Chemical Society reviews.

[64]  Takayoshi Suzuki,et al.  Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. , 2009, Journal of the American Chemical Society.

[65]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[66]  M. Hojjat-Farsangi Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies , 2014, International journal of molecular sciences.

[67]  Richard J. Marhöfer,et al.  Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. , 2013, Journal of medicinal chemistry.

[68]  Tao Wang,et al.  Fragment-based drug discovery and molecular docking in drug design. , 2015, Current pharmaceutical biotechnology.

[69]  P. Taylor,et al.  Synthesis of Selective Agonists for the α7 Nicotinic Acetylcholine Receptor with In Situ Click-Chemistry on Acetylcholine-Binding Protein Templates , 2012, Molecular Pharmacology.

[70]  A. Nairn,et al.  Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase. , 2013, Journal of medicinal chemistry.

[71]  Takayoshi Suzuki,et al.  Epigenetic control using natural products and synthetic molecules. , 2006, Current medicinal chemistry.

[72]  Zoran Radić,et al.  In situ click chemistry: enzyme inhibitors made to their own specifications. , 2004, Journal of the American Chemical Society.

[73]  Kristian Helin,et al.  Histone lysine demethylases as targets for anticancer therapy , 2013, Nature Reviews Drug Discovery.

[74]  B. Dymock,et al.  Selective JAK inhibitors. , 2014, Future medicinal chemistry.

[75]  C. Supuran,et al.  Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? , 2012, Chemical reviews.

[76]  Jane R Kenny,et al.  Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. , 2013, Journal of medicinal chemistry.

[77]  Ruibo Wu,et al.  Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor , 2014, ACS chemical biology.

[78]  S. Turk,et al.  Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. , 2014, Journal of medicinal chemistry.

[79]  R. Liskamp,et al.  Directed Modulation of Protein Kinase C Isozyme Selectivity with Bisubstrate‐Based Inhibitors , 2012, ChemMedChem.

[80]  Janez Konc,et al.  Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. , 2012, Journal of medicinal chemistry.

[81]  Kyle V. Butler,et al.  Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. , 2010, Journal of the American Chemical Society.

[82]  Yukihiro Itoh,et al.  Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. , 2013, Angewandte Chemie.

[83]  Swati S. More,et al.  Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. , 2014, Journal of medicinal chemistry.

[84]  Takayoshi Suzuki,et al.  Explorative study on isoform-selective histone deacetylase inhibitors. , 2009, Chemical & pharmaceutical bulletin.

[85]  Makoto Hasegawa,et al.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.

[86]  Eddy Petit,et al.  Carbonic anhydrase-encoded dynamic constitutional libraries: toward the discovery of isozyme-specific inhibitors. , 2009, Journal of medicinal chemistry.

[87]  Yukihiro Itoh,et al.  Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. , 2006, Journal of medicinal chemistry.

[88]  M. Mathieu,et al.  Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. , 2014, Journal of medicinal chemistry.

[89]  S. Grant,et al.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. , 2014, Pharmacology & therapeutics.

[90]  C. Klein,et al.  Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments. , 2014, Journal of medicinal chemistry.